OncLive® On Air
Claim This Podcastby OncLive® On Air
Podcast Authority
Beta
Podcast Overview
<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>
Language
🇺🇲
Publishing Since
7/10/2018
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
BetaRecommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified phone number on file for OncLive® On Air
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 21, 2026
S17 Ep59: ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
<div> <p>Highlights from the PER® CME activity "ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.</p><p>In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; and Ulka Vaishampayan, MD, FASCO; discuss emerging antibody-drug conjugates and bispecific agents in lung, breast, endometrial, and prostate cancers, and how these agents may shift the therapeutic landscape in these disease.</p><p>Earn CME credit by completing the full accredited activity (available through June 30, 2027): <a href="https://www.gotoper.com/courses/adcs-and-bispecific-antibodies-across-solid-tumors-integrating-new-targets-new-data-and-new-decisions-xqku">https://www.gotoper.com/courses/adcs-and-bispecific-antibodies-across-solid-tumors-integrating-new-targets-new-data-and-new-decisions-xqku</a><br>This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from BioNTech.</p><p>This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.</p></div>
July 20, 2026
S17 Ep58: DLBCL 2026 UPDATE
Two Onc Docs delivers a comprehensive, board-focused review of DLBCL for 2026, updating their prior coverage to reflect several recent practice changes.
July 20, 2026
S17 Ep57: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC
<div> <p>Highlights from the PER® CME activity "Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.</p><p>In this podcast, experts Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; and Paula A. Ugalde Figueroa, MD; discuss evolving immunotherapy strategies for stage I to III non–small cell lung cancer (NSCLC), spanning surgical work-up and the shifting definition of resectability, perioperative immunotherapy trial data, the way that pathologic response guides treatment decisions, and the integration of radiation with immunotherapy in unresectable disease.</p><p>Earn CME credit by completing the full accredited activity (available through June 30, 2027): <a href="https://www.gotoper.com/courses/tumor-board-evolving-immunotherapy-strategies-for-stage-i-iii-nsclc-1">https://www.gotoper.com/courses/tumor-board-evolving-immunotherapy-strategies-for-stage-i-iii-nsclc-1</a><br>This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AstraZeneca Pharmaceuticals.</p><p>This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.</p></div>
880 total episodes available with 36 transcripts
Similar Podcasts
Discover related shows you might enjoy
ASCO Daily News
American Society of Clinical Oncology (ASCO)
Two Onc Docs
Sam and Karine
Oncology Brothers
Oncology Brothers
Oncology Today with Dr Neil Love
Dr. Neil Love
Research To Practice | Oncology Videos
Dr Neil Love
Lung Cancer Considered
IASLC
The Readout Loud
STAT
OncoPharm
John Bossaer
Journal of Clinical Oncology (JCO) Podcast
American Society of Clinical Oncology (ASCO)
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
JAMA Clinical Reviews
JAMA Network
ASCO Guidelines
American Society of Clinical Oncology (ASCO)
The Clinical Problem Solvers
The Clinical Problem Solvers
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
NEJM This Week
NEJM Group
Deep-dive analytics for OncLive® On Air
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is OncLive® On Air?
<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.